Related Experiment Videos
Cytokines and sepsis: pathophysiology and therapy
1Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine, New England Medical Center Hospital, Boston, MA 02111.
New Horizons (Baltimore, Md.)
|February 1, 1993
Summary
Sepsis treatments are lacking, causing high mortality. Targeting immune mediators like interleukin-1 and tumor necrosis factor shows promise for treating sepsis and inflammatory diseases.
Area of Science:
- Immunology
- Critical Care Medicine
- Pharmacology
Background:
- Sepsis exhibits a high mortality rate, exceeding 50% in septic shock patients.
- Endogenous cytokine overproduction significantly contributes to sepsis-induced organ damage.
- Interleukin-1 (IL-1) and tumor necrosis factor (TNF) are key synergistic mediators in sepsis pathophysiology.
Purpose of the Study:
- To evaluate the efficacy of anticytokine therapies in managing sepsis.
- To investigate the role of IL-1 and TNF modulation in treating inflammatory diseases.
Main Methods:
- Review of current therapeutic strategies for sepsis.
- Analysis of preclinical and clinical data on anticytokine agents.
- Focus on strategies targeting IL-1 and TNF.
Main Results:
- Preliminary data suggest anticytokine therapies offer potential benefits.
- Modulation of IL-1 and TNF has shown promising outcomes in early studies.
- These strategies are being explored for sepsis and other inflammatory conditions.
Conclusions:
- Current sepsis therapies are inadequate, necessitating novel approaches.
- Anticytokine strategies targeting IL-1 and TNF represent a promising therapeutic avenue.
- Further research is warranted to optimize anticytokine treatments for sepsis and inflammatory diseases.